Results 131 to 140 of about 34,696 (251)

Evidence for direct and sleep‐moderated relationships between aquaporin‐4 genetic variants and Alzheimer's disease phenotypes

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Variants in the aquaporin‐4 gene (AQP4) have been associated with Alzheimer's disease (AD) diagnosis, cognition, and brain amyloid beta (Aβ) and may affect the sleep and Aβ relationship. Their association with other AD‐related phenotypes/disease progression remain largely unknown.
Tenielle Porter, Ayeisha Milligan Armstrong, Eleanor K. O'Brien, Vincent Doré, Pierrick Bourgeat, Mitchell Turner, Paul Maruff, Christopher C. Rowe, Belinda M. Brown, Victor L. Villemagne, Stephanie R. Rainey‐Smith, Simon M. Laws, AIBL Research Group   +12 more
wiley   +1 more source

Protein-based Radiopharmaceuticals that target fibroblast activation protein alpha: a review of current progress

EJNMMI Radiopharmacy and Chemistry
Background Fibroblast activation protein alpha (FAP) is a serine protease that is expressed at basal levels in benign tissues but is overexpressed in a variety of pathologies, including cancer.
Abdelrahman Homedan, Darpan N. Pandya, Nicholas J. Schnicker, Thaddeus J. Wadas   +3 more
doaj   +1 more source

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract Patients with atypical variants of Alzheimer's disease (AD) often present at a younger age with predominantly non‐amnestic impairments and a more aggressive disease course. Historically, individuals with atypical presentations have not been included in large‐scale clinical trials, which typically focus on late‐onset, sporadic amnestic ...
Nick Corriveau‐Lecavalier, Neus Falgàs, Deepti Putcha, Jonathan Graff‐Radford, Keir X. X. Yong, Baayla D. C. Boon, Rosaleena Mohanty, Eric Westman, Colin Groot, David T. Jones, Lea T. Grinberg, Gil D. Rabinovici, Jennifer L. Whitwell, Liana G. Apostolova, Melissa E. Murray, Dustin B. Hammers, Suzanne E. Schindler, Inga Atonsdottir, Elizabeth K. Rhodus, Jonathan M. Schott, Ignacio Illán‐Gala, Ogbuagu Chukwuanugo, Jorge J. Llibre Guerra, Ruth Peters, Erin L. Abner, Carla Abdelnour, Albert Lladó, Renaud La Joie, Leonardo Cruz de Souza, Neguine Rezaii, Dror Shir, Yolande A. L. Pijenburg, Maria C. Carrillo, Bradford C Dickerson, Paul Aisen, Rik Ossenkoppele, Rema Raman   +36 more
wiley   +1 more source

Provider and patient perspectives on the diagnosis and treatment of Alzheimer's disease: A global perspective from the Global Alzheimer's Leadership Series (GoALS)

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract Since 2016, the Alzheimer's Association and the Fondation Alzheimer have hosted Global Alzheimer's Leadership Series (GoALS) global think tanks, with world‐leading experts for innovative discussions to advance Alzheimer's disease (AD) research and care.
Philippe Amouyel, Sandrine Andrieu, Angela Bradshaw, Ralph C. Carmona, Magali Dumont, Lea Tenenholz Grinberg, Takeshi Iwatsubo, Oskar Hansson, Clifford R Jack Jr, Gregory A Jicha, Simin Mahinrad, Eric McDade, Catherine J Mummery, Ronald C Petersen, Shelagh Robinson, Julie A. Schneider, Lenny Shellcross, Amanda G Smith, Heather M. Snyder, Beth Tapply, Charlotte Teunissen, Wiesje M. van der Flier, Bruno Vellas, David Wallon, Jeff D Williamson, Donna Wilcock, Maria C. Carrillo   +26 more
wiley   +1 more source

Sterically chained amino acid-rich water-soluble carbon quantum dots as a robust tumor-targeted drug delivery platform

Nature Communications
Effective antitumor nanomedicines maximize therapeutic efficacy by prolonging drug circulation time and transporting drugs to target sites. Although numerous nanocarriers have been developed for accurate tumor targeting, their limited water solubility ...
Wenjing Xie, Haoyu Wang, Huimin Xu, Wen Su, Ting Yuan, Jianqiao Chang, Yiqi Bai, Yixiao Fan, Yang Zhang, Yunchao Li, Xiaohong Li, Louzhen Fan   +11 more
doaj   +1 more source

Intraindividual cognitive variability predicts amyloid beta, tau PET, and dementia conversion in Down syndrome: a potential marker of cognitive resilience

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Adults with Down syndrome (DS) are at risk for Alzheimer's disease (AD), yet identifying the preclinical phase remains challenging. Intraindividual cognitive variability (IICV) may be a sensitive marker of early AD‐related changes but remains understudied in DS.
Luciana Mascarenhas Fonseca, Eardi Lila, Ali Shojaie, Jasmeer Chhatwal, Orestes Forlenza, Michal Schnaider Beeri, Sharon Krinsky‐McHale, Ann D. Cohen, Bradley T. Christian, Elizabeth Head, Mark Mapstone, Benjamin Handen, Beau M. Ances, Thomas Grabowski, Naomi S. Chaytor, Shahid Zaman, for the Alzheimer's Biomarkers Consortium‐ Down Syndrome (ABC‐DS) Investigators   +16 more
wiley   +1 more source

Association of cognitive impairment and APOE ε4 with Centiloids in Hispanic and non‐Hispanic White cohorts

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Weak associations of apolipoprotein E (APOE) ε4 with cognitive impairment have been reported in Hispanic cohorts. To determine if APOE ε4 associates with brain amyloid load differently in Hispanic and non‐Hispanic White (NHW) cohorts, we analyzed reported Centiloid values from studies that conducted amyloid positron emission ...
Cally Xiao, Tyler Ard, Ganna Blazhenets, Renaud La Joie, Ioannis Pappas, Arthur W. Toga, the Alzheimer's Disease Neuroimaging Initiative, the Health and Aging Brain Study (HABS‐HD) Study Team   +7 more
wiley   +1 more source

Síntese e caracterização de um novo ligante aminofenólico de interesse farmacológico [PDF]

, 2005
TCC (graduação) - Universidade Federal de Santa Catarina. Centro de Ciências Físicas e Matemáticas. Curso de Química.O potencial de aplicação de fármacos inorgânicos em medicina nuclear e ressonância magnética para diagnóstico e/ou terapia é muito amplo.
LOPES, Silvia Herartt
core  

Prognostic Value of Next‐Generation Flow Cytometry Versus Dual‐Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT To evaluate the comparative prognostic utility of next‐generation flow cytometry (NGF) and dual‐tracer PET/CT in measuring minimal residual disease (MRD), this prospective real‐world study enrolled 118 newly diagnosed multiple myeloma (NDMM) patients. Patients underwent post‐treatment assessment using NGF (sensitivity 10−5) and dual‐tracer PET/
Runfeng Zhang, Wenjia Zhu, Lili Cheng, Jianhua Du, Fujing Zhang, Qiao Yang, Huijuan Wang, Yun Leng, Miao Chen, Li Huo, Junling Zhuang   +10 more
wiley   +1 more source

ERDHEIM‐Chester Disease: Two Fatal Cases With Unusual Presentations

Clinical Case Reports, Volume 14, Issue 6, June 2026.
Fluorodeoxyglucose positron emission tomography‐computed tomography (FDG PET‐CT) demonstrated markedly increased metabolic activity in serosal surfaces including pericardium, pleura, and renal fascia, as well as diffuse uptake along vascular walls, particularly the entire aorta.
Ribero‐Vargas Daniel Andres, C. Álvarez Payares José, Murillo‐Pérez Juliana   +2 more
wiley   +1 more source